Welcome to our dedicated page for Whitehawk Therapeutics news (Ticker: WHWK), a resource for investors and traders seeking the latest updates and insights on Whitehawk Therapeutics stock.
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) is a clinical-stage oncology therapeutics company developing antibody-drug conjugate (ADC) cancer treatments, and its news flow reflects this focus on targeted oncology and biomarker-driven research. Company updates highlight progress across an advanced three-asset ADC portfolio targeting clinically validated proteins PTK7, MUC16 and SEZ6 in solid tumors.
Investors and observers following WHWK news will see announcements on key clinical and regulatory milestones, such as clearance of the Investigational New Drug (IND) application for the PTK7-targeted ADC HWK-007 and the submission of an IND for the MUC16-targeted ADC HWK-016. News also covers the start and design of Phase 1, multicenter, open-label trials in adults with advanced or metastatic solid tumors that are refractory to standard therapies, including initial evaluation in lung, ovarian and endometrial cancers for HWK-007 and high MUC16-expressing gynecologic cancers for HWK-016.
Whitehawk’s releases further include scientific updates, such as presentation of a real-world analysis confirming PTK7 as a broadly expressed, clinically relevant target across solid tumors at the AACR-NCI-EORTC conference, and collaboration announcements like its multi-year agreement with Tempus AI to support biomarker-driven oncology research. Corporate news items feature financial results, participation in healthcare and biotechnology investor conferences, and senior leadership appointments related to clinical development.
This WHWK news page aggregates these types of developments so readers can review regulatory updates, clinical trial progress, scientific presentations, collaborations and financial disclosures in one place. For those tracking ADC-focused oncology companies, it provides a centralized view of Whitehawk Therapeutics’ reported activities and milestones over time.
Whitehawk Therapeutics (Nasdaq: WHWK) presented a real-world analysis at ASCO 2026 showing seizure related homolog protein 6 (SEZ6) is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors.
Data indicate SEZ6 expression exceeds other approved and emerging ADC targets and correlates with DLL3, supporting development of SEZ6-directed ADC HWK-206, with an IND filing expected mid-2026 and a Phase 1 trial planned for Q3 2026.
Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will present at the Jefferies 2026 Global Healthcare Conference in New York City on Thursday, June 4 at 8:10 AM ET.
A live and replay webcast will be available on the company’s IR website for ~30 days.
Whitehawk Therapeutics (Nasdaq: WHWK) entered an option agreement with Hangzhou DAC for access to CPT113 in up to five new, internally developed ADC programs, including possible dual‑payloads. Whitehawk keeps global rights and program control and plans multiple IND filings over the next 12‑24 months.
Phase 1 dose‑escalation trials of HWK‑007 and HWK‑016 are enrolling, with data expected in 1H 2027. External programs DXC006 and JNJ‑95437446 also use CPT113, supporting confidence in Whitehawk's ADC platform and its CBCR bioconjugation process.
Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will join a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026, at 11:00 AM ET.
A live webcast and 30-day replay will be available via the company’s investor relations website.
Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will join a virtual fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026, at 3 PM ET. A live and replay webcast will be available on the investor relations website.
Whitehawk Therapeutics (Nasdaq: WHWK) entered a securities purchase agreement for an approximately $87.5 million private placement equity financing with qualified institutional buyers and accredited investors. The PIPE includes 4,330,866 common shares at $3.92 and 17,991,021 pre-funded warrants at $3.9199, exercisable at $0.0001 per share.
According to Whitehawk, closing is expected on May 14, 2026, subject to customary conditions. Net proceeds, combined with existing cash and marketable securities, are intended for working capital, general corporate purposes and ADC pipeline development, and are projected to extend the cash runway into the second half of 2028.
Whitehawk Therapeutics (Nasdaq: WHWK) reported Q1 2026 results and pipeline progress on May 7, 2026. Cash, cash equivalents and short-term investments were $123.0 million as of March 31, 2026, projected to fund operations into 2028. Ongoing Phase 1 dose-escalation trials for HWK-007 and HWK-016 continue; an IND for HWK-206 is planned for mid-2026 with Phase 1 recruitment targeted in Q3 2026. Preclinical data presented at AACR 2026 support potency, plasma stability and tolerability for the ADC portfolio. R&D expense rose to $17.2 million in Q1 2026; net loss was $22.2 million.
Whitehawk Therapeutics (Nasdaq: WHWK) presented preclinical AACR 2026 data for three next-generation ADCs: HWK-007, HWK-016 and HWK-206. Key findings include tumor regressions at low single-digit mg/kg doses, high plasma stability (free payload ≤0.01% AUC), and favorable tolerability in non-human primates with an HNSTD of 60 mg/kg.
The company is conducting Phase 1 trials for HWK-007 and HWK-016; an IND filing for HWK-206 is on track for mid-2026 with a planned Phase 1 start in Q3 2026.
Whitehawk Therapeutics (Nasdaq: WHWK) said Dave Lennon, PhD, President and CEO, will appear in a virtual fireside chat on Thursday, April 23, 2026 at 3:00 PM ET as part of the Jones Trading Post-AACR Fireside Chat Series.
A live webcast is accessible via the company investor relations website and will be available for replay for approximately 30 days.
Whitehawk Therapeutics (Nasdaq: WHWK) presented real-world analyses at SGO 2026 showing MUC16 is highly and stably expressed in ovarian and endometrial cancers, often exceeding other ADC targets by 2- to >100-fold.
Findings support development of HWK-016, a next-generation MUC16-targeted ADC in Phase 1 for advanced ovarian and endometrial cancers, with initial clinical data expected in H1 2027.